DOV Pharmaceutical Inc. (DOVP/DOVP.PK) Wrap Up:

DOV Pharmaceutical, Inc., a biopharmaceutical company, engages in the discovery, in-licensing, and development of novel drug candidates for central nervous system disorders. Its product candidate include DOV 21,947, a triple reuptake inhibitor, which is in Phase II clinical trials for depression, as well as in preclinical studies for obesity; Bicifadine for the treatment of pain or analgesics, which is in Phase II/Phase III(2) clinical trials; DOV diltiazem for the treatment of hypertension and angina is in Phase I/III(3); and DOV 102,677, which is in Phase I(4) for alcohol abuse. The company also involves in the preclinical discovery and development programs, such as DOV 216,419 which is in Pre-IND(5) preclinical trails for depression and pain; and Uptake inhibitors and GABA modulators for various central nervous system disorders. In addition, DOV Pharmaceutical develops Indiplon, a program subject to regulatory review for the treatment of insomnia. It has strategic collaborations and licensing agreements with XTL Biopharmaceuticals, Inc., for bicifadine; Blue Note Pharmaceuticals, Inc., for DOV diltiazem; and Neurocrine Biosciences, Inc., for indiplon, as well as Wyeth Holdings Corporation. The company was founded in 1995 and is headquartered in Somerset, New Jersey.